Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander J Thompson

Showing results (131-140 of 175) with videos related to

Pageof 18
Sort By:
Hepatology (Baltimore, Md.)|February 15, 2012
Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic responseSusanna Naggie, Anu Osinusi, Antonios Katsounas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 25, 2019
Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject DrugsAmanda J Wade, Joseph S Doyle, Edward Gane, et al.
Plos One|July 1, 2020
The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health servicesMichael W Traeger, Alisa E Pedrana, Daniela K van Santen, et al.
Clinical Liver Disease|October 17, 2022
Validation of novel point-of-care test for alanine aminotransferase measurement: A pilot cohort studyJessica Howell, Huy Van, Minh Pham, et al.
The Lancet. Infectious Diseases|December 5, 2025
Best practice guidelines for viral hepatitis service delivery in prisonsYumi Sheehan, Akhil Garg, Julia Sheehan, et al.
Hepatology (Baltimore, Md.)|January 22, 2011
Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment responseJama M Darling, Jeroen Aerssens, Gregory Fanning, et al.
Hepatology (Baltimore, Md.)|January 29, 2011
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVRAlexander J Thompson, Rosanna Santoro, Valeria Piazzolla, et al.
Plos One|November 18, 2020
Non-invasive fibrosis algorithms are clinically useful for excluding cirrhosis in prisoners living with hepatitis CTimothy Papaluca, Anne Craigie, Lucy McDonald, et al.
Nature|February 23, 2010
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis CJacques Fellay, Alexander J Thompson, Dongliang Ge, et al.
Journal of Gastroenterology and Hepatology|January 11, 2013
IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-αJacinta A Holmes, Tin Nguyen, Dilip Ratnam, et al.
Pageof 18

Showing results (131-140 of 175) with videos related to

Sort By:
Pageof 18
Hepatology (Baltimore, Md.)|February 15, 2012
Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic responseSusanna Naggie, Anu Osinusi, Antonios Katsounas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 25, 2019
Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject DrugsAmanda J Wade, Joseph S Doyle, Edward Gane, et al.
Plos One|July 1, 2020
The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health servicesMichael W Traeger, Alisa E Pedrana, Daniela K van Santen, et al.
Clinical Liver Disease|October 17, 2022
Validation of novel point-of-care test for alanine aminotransferase measurement: A pilot cohort studyJessica Howell, Huy Van, Minh Pham, et al.
The Lancet. Infectious Diseases|December 5, 2025
Best practice guidelines for viral hepatitis service delivery in prisonsYumi Sheehan, Akhil Garg, Julia Sheehan, et al.
Hepatology (Baltimore, Md.)|January 22, 2011
Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment responseJama M Darling, Jeroen Aerssens, Gregory Fanning, et al.
Hepatology (Baltimore, Md.)|January 29, 2011
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVRAlexander J Thompson, Rosanna Santoro, Valeria Piazzolla, et al.
Plos One|November 18, 2020
Non-invasive fibrosis algorithms are clinically useful for excluding cirrhosis in prisoners living with hepatitis CTimothy Papaluca, Anne Craigie, Lucy McDonald, et al.
Nature|February 23, 2010
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis CJacques Fellay, Alexander J Thompson, Dongliang Ge, et al.
Journal of Gastroenterology and Hepatology|January 11, 2013
IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-αJacinta A Holmes, Tin Nguyen, Dilip Ratnam, et al.
Pageof 18